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Background. Lack of a gold standard for identifying bacterial and viral etiologies of pneumonia has limited evaluation of 
C-reactive protein (CRP) for identifying bacterial pneumonia. We evaluated the sensitivity and specificity of CRP for identifying 
bacterial vs respiratory syncytial virus (RSV) pneumonia in the Pneumonia Etiology Research for Child Health (PERCH) multi-
center case-control study.
Methods. We measured serum CRP levels in cases with World Health Organization–defined severe or very severe pneumonia 
and a subset of community controls. We evaluated the sensitivity and specificity of elevated CRP for “confirmed” bacterial pneumo-
nia (positive blood culture or positive lung aspirate or pleural fluid culture or polymerase chain reaction [PCR]) compared to “RSV 
pneumonia” (nasopharyngeal/oropharyngeal or induced sputum PCR-positive without confirmed/suspected bacterial pneumonia). 
Receiver operating characteristic (ROC) curves were constructed to assess the performance of elevated CRP in distinguishing these 
cases.
Results. Among 601 human immunodeficiency virus (HIV)–negative tested controls, 3% had CRP ≥40 mg/L. Among 119 HIV-
negative cases with confirmed bacterial pneumonia, 77% had CRP ≥40 mg/L compared with 17% of 556 RSV pneumonia cases. 
The ROC analysis produced an area under the curve of 0.87, indicating very good discrimination; a cut-point of 37.1 mg/L best dis-
criminated confirmed bacterial pneumonia (sensitivity 77%) from RSV pneumonia (specificity 82%). CRP ≥100 mg/L substantially 
improved specificity over CRP ≥40 mg/L, though at a loss to sensitivity.
Conclusions. Elevated CRP was positively associated with confirmed bacterial pneumonia and negatively associated with RSV 
pneumonia in PERCH. CRP may be useful for distinguishing bacterial from RSV-associated pneumonia, although its role in dis-
criminating against other respiratory viral-associated pneumonia needs further study.
Keywords. C-reactive protein; bacteria; RSV; biomarker; pneumonia.
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C-reactive protein (CRP) is an acute phase plasma protein syn-
thesized by hepatocytes and adipocytes in response to inflam-
matory cytokines and is an indicator of acute inflammation 
[1]. First identified in sera from pneumonia patients in 1930 by 
its ability to precipitate the C-polysaccharide of Streptococcus 
pneumoniae [2], CRP has since been associated with bacte-
rial infections generally [3] and with noninfectious causes of 
inflammation [1, 4]. These associations have led to the use of 
CRP for discriminating between bacterial and nonbacterial 
pneumonia.
Several studies have found higher CRP levels in bacterial 
than viral pneumonia [5–16], whereas others have not [17–19]. 
Even in those detecting a difference, overlapping CRP distri-
butions indicate imperfect specificity for bacterial pneumonia. 
The variation in reported utility of CRP for distinguishing etio-
logic class in pneumonia likely results from small sample sizes, 
lack of specific tests for accurately categorizing bacterial and 
viral pneumonia, and differences across studies in case groups, 
severity of disease, and comparison groups.
The Pneumonia Etiology Research for Child Health 
(PERCH) study provides an opportunity to examine the associ-
ation between CRP and etiology of pneumonia in a number of 
children in several countries [20]. We describe the distribution 
of CRP among PERCH cases and a subset of community con-
trols and examine factors associated with elevated CRP among 
both groups. We also evaluate the sensitivity and specificity of 
elevated CRP for bacterial pneumonia in comparison to pneu-
monia likely caused by respiratory syncytial virus (RSV), the 
most common respiratory virus associated with childhood 
pneumonia [21].
METHODS
PERCH evaluated etiologic agents causing severe and very severe 
pneumonia among children <5 years of age in 9 sites across 7 
countries: Dhaka and Matlab, Bangladesh; Basse, The Gambia; 
Kilifi, Kenya; Bamako, Mali; Soweto, South Africa; Nakhon 
Phanom and Sa Kaeo, Thailand; and Lusaka, Zambia [20].
Identification and selection of cases and controls have been 
described previously [22]. In brief, cases were hospitalized 
children aged 1–59  months with World Health Organization 
(WHO)–defined severe or very severe pneumonia [23]. 
Controls were randomly selected children from the commu-
nity without severe or very severe pneumonia and frequency 
matched by age and month of enrollment to cases. In South 
Africa and Zambia where the human immunodeficiency virus 
(HIV) prevalence was high, controls were also frequency 
matched on HIV.
Blood, nasopharyngeal/oropharyngeal (NP/OP) swabs, and 
induced sputum were collected from PERCH cases at enroll-
ment. Pleural fluid was collected from cases when clinically 
indicated. Lung aspirates were collected among a subset of cases 
meeting eligibility criteria [24] at the Bangladesh, The Gambia, 
Mali, and South Africa sites. Blood and NP/OP swabs were col-
lected from PERCH controls.
Pathogen-specific testing methods by body fluid have also 
been described elsewhere [25]. In brief, NP/OP, induced spu-
tum, lung aspirates, and pleural fluid were tested by quantitative 
real-time polymerase chain reaction (PCR) using the Fast Track 
Diagnostics Respiratory Pathogens 33 test (FTD Resp-33) (Fast-
track Diagnostics, Sliema, Malta) for select viruses and bacteria. 
Lung aspirates and pleural fluid were also tested by Gram stain 
and bacterial culture. Whole blood among cases and controls 
was tested by real-time PCR for pneumococcus only; blood cul-
tures were performed on cases using standardized automated 
systems.
CRP levels were measured in all PERCH cases from whom 
serum specimens were collected. To assess specificity for bacte-
rial pneumonia, we evaluated elevated CRP among those most 
likely to have viral pneumonia, cases with RSV pneumonia 
(defined below). We also assessed CRP specificity by testing sera 
from a subset of community controls at each site, children who 
by definition did not have severe or very severe pneumonia, 
whether bacterial or otherwise. The subset of controls tested 
for CRP was enriched with children potentially more likely to 
have elevated CRP. This was achieved by oversampling from 
those who were positive for pneumococcus by whole-blood 
PCR, had a respiratory tract illness (defined below), had a total 
NP/OP PCR pathogen load (across all pathogens tested for) in 
the top 25% of controls at each site, or who were HIV-infected. 
Serum samples from South Africa were tested locally using 
CRP Gen3 Immunoturbidometric assay (Roche Diagnostics, 
Milan, Italy). Serum specimens from the other sites were tested 
for CRP at the PERCH reference laboratory in Christchurch, 
New Zealand, using CRP VARIO Immunoturbidometric assay 
(Roche Diagnostic, Milan, Italy).
Definitions
Respiratory tract illness (RTI) in controls was defined as having 
cough or runny nose. RTI was also defined as having (1) at least 
1 of ear discharge, wheezing, or difficulty breathing and (2) 
either a measured temperature of ≥38.0°C within the previous 
48 hours or a history of sore throat. Chest radiograph positive 
(CXR+) was defined as chest radiograph performed up to 72 
hours after presentation at study sites with evidence of alveo-
lar consolidation (CXR-AC) or any other infiltrate (CXR-OI) 
by the WHO interpretation criteria [26, 27]. Confirmed bac-
terial pneumonia was defined as any noncontaminant bacte-
rial pathogen detected by culture of blood; by PCR or culture 
of lung aspirate; or by PCR, culture, or pneumococcal antigen 
detection (BinaxNOW) of pleural fluid. Confirmed viral pneu-
monia was defined as any virus detected from lung aspirate or 
pleural fluid by PCR. Suspected bacterial pneumonia cases were 
cases who met all the following criteria: RSV-negative by NP/
OP and induced sputum PCR; absence of confirmed bacterial 
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and confirmed viral pneumonia; and NP/OP PCR Streptococcus 
pneumoniae (Spn) density >106.9 copies/mL or whole-blood 
PCR Spn density >102.2 copies/mL or NP/OP PCR Haemophilus 
influenzae (Hinf) density >105.9 copies/mL (these PERCH 
thresholds that distinguished bacterial pneumonia cases due 
to Spn and Hinf from controls are described elsewhere in this 
supplement [28–30]). Respiratory syncytial virus positivity 
(RSV+) was defined as detection of RSV by PCR from NP/
OP or induced sputum. For the purpose of this analysis, RSV 
pneumonia was defined as RSV+ cases without any of the fol-
lowing: confirmed bacterial pneumonia; high-density Spn (NP/
OP PCR Spn density >106.9 copies/mL or whole-blood PCR Spn 
density >102.2 copies/mL); and high-density Hinf (NP/OP PCR 
Hinf density >105.9 copies/mL).
Statistical Analysis
Analyses were restricted to HIV-negative cases and controls 
unless otherwise noted. We evaluated the association of demo-
graphic and clinical factors with CRP ≥40 mg/L among CXR+ 
cases and among controls using logistic regression to adjust for 
age and site, with CRP ≥40 mg/L as the outcome. We also com-
pared these characteristics among controls tested vs not tested 
for CRP. Because the subset of controls selected for CRP testing 
intentionally targeted elevated CRP, the proportion with ele-
vated CRP is not representative of the prevalence in children in 
the community; therefore, we did not compare the distribution 
of CRP results between cases and controls.
Because there is no gold standard for determining viral eti-
ology and because RSV was the only virus strongly associated 
with case-control status (odds ratio >7.0 at every site), we lim-
ited analyses of viral pneumonia to just RSV-associated pneu-
monia cases. We calculated the proportion of children with 
elevated CRP among subgroups with increasing likelihood of 
bacterial pneumonia (and decreasing likelihood of RSV pneu-
monia): CXR-normal cases, CXR-OI cases (without CXR-AC), 
and CXR-AC cases (with or without CXR-OI). We assessed 
the performance of CRP in distinguishing confirmed bacte-
rial pneumonia from RSV pneumonia using receiver operating 
characteristic (ROC) analysis with the area under the curve 
(AUC) statistic [31]; the Youden index was used to determine 
the best differentiating cut-point [32]. To guard against bias in 
the estimates of sensitivity due to small numbers of confirmed 
cases, the Youden index was calculated using leave-one-out 
cross-validation where applicable [33].
Using Spn as an example, we explored whether additionally 
requiring elevated CRP could improve the specificity of patho-
gen-specific measures of high pathogen load (NP/OP Spn PCR 
density >106.9 copies/mL; whole-blood Spn PCR density >102.2 
copies/mL) to identify Spn pneumonia. We compared the joint 
positivity of elevated CRP and high pathogen load among cases 
with confirmed Spn pneumonia to RSV+ cases that did not have 
a confirmed bacterial infection but may have had high-density 
Spn or Hinf. We also compared joint positivity among cases to 
the subset of controls that were selected for CRP testing.
Statistical analyses were performed using SAS software ver-
sion 9.4 (SAS Institute, Cary, North Carolina). All P values pro-
vided were obtained from logistic regression analyses adjusting 
for age and site unless otherwise noted.
Ethical Considerations
The PERCH study protocol was approved by the institutional 
review board or ethical review committee at each of the study 
site institutions and at the Johns Hopkins Bloomberg School of 
Public Health. Parents or guardians of all participants provided 
written informed consent.
RESULTS
Among 3981 HIV-negative cases, 3357 (84%) had CRP 
measured. CRP ≥40  mg/L was observed in 28% of all HIV-
negative cases and was more frequent among CXR+ cases 
(35%) than among CXR-normal cases (20%, P < .001; Table 1). 
CRP ≥100 mg/L was found in 11% of all HIV-negative cases and 
again was more common among CXR+ cases (15%) than CXR-
normal cases (6%, P < .001; data not shown).
Factors Associated With Elevated CRP
CRP ≥40  mg/L was associated with HIV status: 45% of 159 
HIV-positive CXR+ cases with available CRP results had 
CRP  ≥40  mg/L compared with 35% of 1508 HIV-negative 
CXR+ cases (P  =  .009). Among HIV-negative CXR+ cases, 
the proportion with CRP ≥40 mg/L was higher at the African 
sites (range, 31% in South Africa to 49% in The Gambia) 
than at Asian sites (13% in Bangladesh and 24% in Thailand). 
Additionally, among HIV-negative CXR+ cases, CRP ≥40 mg/L 
was more common among older children and those with very 
severe pneumonia, fever, or absence of wheeze (all P  ≤  .001, 
adjusted for site and age; Supplementary Table  1). Among 
HIV-positive CXR+ cases, CRP ≥40 mg/L was similarly more 
common among older children and those with very severe 
pneumonia (P = .01 and P = .03, respectively, adjusted for site 
and age; data not shown).
CRP Results Among Targeted Community Controls
By design, the 601 HIV-negative controls tested for CRP were 
more likely to have RTI (43%) and be PCR-positive for pneumo-
coccus in whole blood (36%) than controls not tested (21% and 
1%, respectively); 69% of tested controls met at least 1 of these 
conditions compared with 23% of controls not tested for CRP 
(Supplementary Table  2). Of tested controls, 12% (95% confi-
dence interval [CI], 9%–15%) had CRP ≥10 mg/L and 3% (95% 
CI, 2%–4%) had CRP ≥40 mg/L. Of several factors examined, 
only pneumococcal PCR positivity in whole blood was associ-
ated with CRP ≥40  mg/L after adjusting for site and age. The 
proportion of tested HIV-negative controls with CRP ≥40 mg/L 
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varied by site, ranging from 0% in Zambia and South Africa to 7% 
in The Gambia. CRP ≥40 mg/L was also more frequent among 
controls who had at least 1 of RTI, NP/OP Spn density >106.9 
copies/mL, or whole-blood PCR positivity for pneumococcus 
(3% vs 1% among controls with none of these characteristics).
Of 221 HIV-positive controls enrolled at the South African 
and Zambian sites, 81 (37%) were tested for CRP. CRP ≥40 mg/L 
was more common among the HIV-positive (11%; 95% CI, 
4%–18%) than the HIV-negative (3%) controls selected for test-
ing across all PERCH sites as was CRP ≥10 mg/L (30% vs 12%, 
data not shown). No factors were found to be associated with 
CRP ≥40  mg/L among the HIV-positive controls, but sample 
size was small (data not shown).
Association of Elevated CRP With Bacterial Versus RSV Pneumonia
Of 842 HIV-negative RSV+ cases, 286 (34%) were excluded 
from the RSV pneumonia case group because they had a con-
firmed bacterial infection (n = 9), high-density Spn in the NP/
OP (n = 111) or whole blood (n = 22), or high-density Hinf in 
the NP/OP (n = 199).
Among 119 HIV-negative cases with confirmed bacterial 
pneumonia, 77% had CRP ≥40  mg/L compared with 17% of 
556 cases with RSV pneumonia (P < .001). Of the 286 excluded 
RSV+ cases, 85 (30%) had CRP ≥40 mg/L.
Among HIV-positive cases, differences were less extreme but 
trends were similar, though small numbers limit interpreta-
tion: 69% of 26 cases with confirmed bacterial pneumonia had 
CRP ≥40 mg/L compared with 45% of 11 cases with RSV pneu-
monia (data not shown; P = .41).
An abnormal chest radiograph was associated with 
CRP ≥40 mg/L among HIV-negative cases with RSV pneumo-
nia (24% of CXR+ vs 12% of CXR-normal cases, P < .001) but 
not cases with confirmed bacterial pneumonia (77% vs 75%; 
Supplementary Table 4). However, among CXR+ cases in both 
groups, the percentage with elevated CRP was higher among cases 
with CXR-AC than cases with CXR-OI: 85% vs 50% (P = .004) 
among confirmed bacterial pneumonia cases and 31% vs 18% 
(P = .01) among RSV pneumonia cases (Figure 1, Supplementary 
Table 4). High CRP (≥100 mg/L) was very common among the 
CXR-AC cases with confirmed bacterial pneumonia (71%) and 
uncommon (4%) among RSV pneumonia cases (Figure 1).
Among the confirmed bacterial pneumonia cases, those 
confirmed for either Spn or Hinf had higher CRP (84% 
CRP  ≥40  mg/L and 74% CRP  ≥100  mg/L) than cases con-
firmed for other bacteria (69% CRP ≥40 mg/L, P = .18 and 45% 
CRP ≥100 mg/L, P = .02; Supplementary Table 5).
ROC analyses showed that CRP had good accuracy in dis-
tinguishing cases with confirmed bacterial infection from RSV 
pneumonia cases (AUC  =  0.87, Figure  2); the CRP cut-point 
that produced optimal differentiation was 37.1 mg/L with a cor-
responding sensitivity of 77% (95% CI, 69%–84%) and speci-
ficity of 82% (95% CI, 78%–85%). When trying to distinguish 
confirmed Spn cases from RSV pneumonia, the AUC increased 
to 0.91; the optimal cut-point was 88.9  mg/L, resulting in a 
sensitivity and specificity of 79% (95% CI, 64%–89%) and 95% 
(95% CI, 93%–97%), respectively. The AUC for distinguishing 
confirmed Hinf cases from RSV pneumonia cases was also 0.91; 
the optimal cut-point of 52.3 mg/L produced a sensitivity and 
specificity of 80% (95% CI, 58%–92%) and 86% (95% CI, 83%–
89%), respectively.
Value of CRP to Increase Specificity of Other Etiology Laboratory 
Measurements
We assessed how combining elevated CRP with Spn density 
measures improved the specificity over Spn density measures 
alone in differentiating confirmed pneumococcal cases from: 
(1) RSV+ cases without confirmed bacterial coinfection and (2) 
community controls tested for CRP. The percentage of RSV+ 
Table 1. Distribution of C-Reactive Protein Among Severe and Very Severe Pneumonia Cases—Pneumonia Etiology Research for Child Health (PERCH) 
Study
CRP Level, mg/L All Cases
CXR Status
P Valued, All CXR+ vs
CXR-NormalCXR-ACa CXR-OIb All CXR+c CXR-Normal
HIV-negative (n = 3357) (n = 729) (n = 769) (n = 1508) (n = 1339)
 <10 1422 (42.4) 204 (27.6) 326 (42.4) 530 (35.2) 640 (47.8) <.001
 10 to <40 1010 (30.1) 199 (26.9) 253 (32.9) 452 (30.0) 435 (32.5)
 ≥40 925 (27.6) 336 (45.5) 190 (24.7) 526 (34.9) 264 (19.7)
HIV-positive (n = 240) (n = 120) (n = 39) (n = 159) (n = 24)
 <10 83 (34.6) 33 (27.5) 13 (33.3) 46 (28.9) 10 (41.7) .98
 10 to <40 59 (24.6) 27 (22.5) 14 (35.9) 41 (25.8) 4 (16.7)
 ≥40 98 (40.8) 60 (50.0) 12 (30.8) 72 (45.3) 10 (41.7)
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: AC, alveolar consolidation; CRP, C-reactive protein; CXR, chest radiograph; HIV, human immunodeficiency virus; OI, other infiltrate.
aCXR-AC: radiographic evidence of alveolar consolidation with or without any other infiltrate.
bCXR-OI: radiographic evidence of any other infiltrate without evidence of alveolar consolidation.
cAll CXR+: radiographic evidence of alveolar consolidation, any other infiltrate, or both (includes both CXR-AC and CXR-OI cases).
dP value comparing CRP <40 vs CRP ≥40 mg/L, adjusted for age and site.
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cases and tested community controls with both CRP ≥40 mg/L 
and high density Spn in the NP/OP was 4% and 1%, respectively, 
compared with 13% and 12%, respectively, with high NP/OP 
density alone. This gain in specificity came without substantial 
loss in sensitivity, declining from 58% of confirmed Spn cases 
with high NP/OP density to 47% who also had CRP ≥40 mg/L 
(Table 2). Less than 1% of RSV+ cases and 0% of tested controls 
had high Spn NP/OP density and CRP ≥100 mg/L compared 
with 42% of confirmed Spn cases.
Because the optimal whole-blood Spn PCR density cut-
point identified in ROC analyses had high specificity as a sin-
gle measure (only 2% of RSV+ cases had high density Spn in 
whole blood), also requiring CRP ≥40 mg/L increased speci-
ficity only minimally (0.4% positive for both measurements). 
However, the gain in specificity was larger when compared 
to the tested community controls: 20% had high-den-
sity Spn in whole blood compared with 0.8% who also had 
CRP ≥40 mg/L.
DISCUSSION
This large study of hospitalized severe and very severe pneu-
monia from 7 countries in Africa and Asia showed that ele-
vated CRP was positively associated with confirmed bacterial 
pneumonia and negatively associated with RSV pneumo-
nia as defined for this analysis. The percentage of cases with 
CRP ≥40 mg/L varied by site, age, HIV status, CXR findings, 
severity, presence of fever, and wheeze. Among community 
controls targeted for CRP testing because of suspected poten-
tial for elevated CRP, the proportion with CRP ≥40 mg/L was 
low (3% among HIV-negative controls and 11% among HIV-
positive controls) but specificity was not 100%.
We conducted this analysis to see if CRP could be a useful 
diagnostic to distinguish bacterial from viral pneumonia. But 
because there is no gold standard for diagnosing viral pneu-
monia, we limited our analysis of viruses solely to RSV since 
RSV was the only viral pathogen assessed that was both rarely 
observed in the NP/OP of controls and strongly associated with 
case status. That evidence suggested RSV was causally associ-
ated with the pneumonia episode in a large fraction of the RSV+ 
cases. However, severe and very severe pneumonia associated 
with RSV may not be representative of pneumonias associated 
with other viruses as viruses might differ in their propensity 
to cause bacterial super- or coinfections. In our analyses, we 
excluded RSV+ cases who may have had bacterial coinfection, 
an important and potentially substantial subgroup of cases with 
bacterial–viral coinfection. Other studies of children with res-
piratory infections that have observed increased CRP levels 
among cases with certain viruses detected have a similar prob-
lem of inability to rule out concurrent bacterial infections and 
inability to confirm viral etiology because of lack of gold stand-
ard tests [34–37]. Because our analyses assessed a case group 
that likely had true RSV pneumonia, we concluded that elevated 
CRP levels were more common in bacterial than RSV pneumo-
nia. However, our conclusions cannot extend to other viruses as 
the negative association found in PERCH between RSV pneu-
monia and elevated CRP may not be true of all viruses.
Another challenge in interpreting elevated CRP was that the 
proportion with CRP ≥40 mg/L varied by bacterial pathogen; 
Figure 1. Percentage of cases with elevated (≥40 mg/L) and high (≥100 mg/L) C-reactive protein by (approximate) increasing likelihood of bacterial etiology. Confirmed bac-
terial pneumonia: bacterial pathogen identified by blood culture, by culture or polymerase chain reaction (PCR) of lung aspirate or pleural fluid, or Streptococcus pneumoniae 
identified by BinaxNOW assay of pleural fluid. Respiratory syncytial virus (RSV) pneumonia: RSV identified by nasopharyngeal/oropharyngeal (NP/OP) PCR or induced sputum 
PCR excluding (1) confirmed bacterial cases and (2) cases with whole-blood pneumococcal density >102.2 copies/mL, or NP/OP pneumococcal PCR density >106.9 copies/mL, 
or Haemophilus influenzae NP/OP PCR density >105.9 copies/mL. Vertical bars: 95% confidence intervals. Abbreviations: CXR+, cases with radiographic evidence of alveolar 
consolidation, any other infiltrate, or both; CXR-AC, cases with radiographic evidence of alveolar consolidation (with or without any other infiltrate); CXR-OI, cases with 
radiographic evidence of any other infiltrate only.
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CRP was higher among cases confirmed for Spn and Hinf than 
cases confirmed for other bacteria. Although sample size was 
limited and the difference was not statistically significant, this 
may suggest that the CRP response could vary by bacterial path-
ogen. However, it is also possible that this indicates imperfect 
specificity of determining bacterial pneumonia, as the major-
ity of the “confirmed” bacterial cases were diagnosed based on 
detection of bacteria in the blood and may not represent the 
infection in the lung.
If the distribution of CRP differs by bacteria, then the relative 
distribution of bacterial etiologies among the cases will affect 
the calculation of CRP cut-points for distinguishing bacterial 
from RSV pneumonia cases. Because the CRP cut-points cal-
culated in this analysis were selected to maximize the sum of 
sensitivity and specificity for our data, they may not be repre-
sentative of other settings and are presented for descriptive pur-
poses only. However, they may have utility in determining or 
corroborating etiology results within the PERCH study.
In clinical practice, a test that has both high specificity and 
sensitivity to identify bacterial infection would be helpful to 
identify those children who would benefit from antibiotic ther-
apy. The WHO definition of severe and very severe pneumonia 
Figure 2. A–D, Receiver operating characteristic curves and area under the curve (AUC) for C-reactive protein in differentiating confirmed bacterial pneumonia from prob-
able respiratory syncytial virus (RSV) pneumonia among human immunodeficiency virus–negative Pneumonia Etiology Research for Child Health (PERCH) cases. aCases with 
any noncontaminant bacteria identified by blood culture, by culture or polymerase chain reaction (PCR) of lung aspirate or pleural fluid, or with Streptococcus pneumoniae 
identified by BinaxNOW assay of pleural fluid. bRSV identified by nasopharyngeal/oropharyngeal (NP/OP) PCR or induced sputum PCR, excluding high-density bacterial cases 
(Streptococcus pneumoniae cases with whole-blood PCR density >102.2 copies/mL, or NP/OP density >106.9 copies/mL, and Haemophilus influenzae cases with NP/OP density 
>105.9 copies/mL) and confirmed bacterial cases. cCases with S. pneumoniae identified by blood culture, by lung aspirate culture or PCR, or by pleural fluid culture or PCR or 
BinaxNOW. dCases with H. influenzae identified by blood culture, by lung aspirate culture or PCR, or by pleural fluid culture or PCR. eCases with a bacterial pathogen identified 
by blood culture, by lung aspirate culture or PCR, or by pleural fluid culture or PCR (excluding confirmed S. pneumoniae and H. influenzae cases).
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was designed to be very sensitive (at the expense of specific-
ity), to identify as many cases of bacterial etiology as possible 
in resource-poor settings for treatment with antibiotics. As a 
result, many cases meeting the definition do not have a bac-
terial infection. While CRP ≥40 mg/L may be a fairly specific 
marker to rule out most RSV pneumonias (83% of RSV pneu-
monia cases had CRP <40 mg/L), it had inadequate sensitivity 
as 23% of cases with confirmed bacterial severe or very severe 
pneumonia also had CRP <40 mg/L. Our findings confirm the 
current consensus in the literature, which is that while CRP is 
elevated in bacterial pneumonia, CRP alone is not sufficient for 
diagnosing bacterial pneumonia.
In addition to being able to distinguish between cases with 
bacterial vs RSV pneumonia, the informative value of CRP in 
etiology studies includes its ability to distinguish between bac-
terial pneumonia cases and controls without pneumonia. CRP 
levels among controls can be used to determine a reasonable 
minimal threshold to serve as a reliable biomarker for bac-
terial pneumonia. Reports of CRP levels in healthy children 
1–59 months in the published literature are few and often have 
limited sample sizes (≤100 controls) or include older children 
[38–42]; thus, this analysis serves to anchor any conclusions on 
the practical application of the utility of CRP levels as a diag-
nostic tool for bacterial pneumonia in this age group. Though, 
because the controls selected for testing in our study delib-
erately targeted those thought to have a higher likelihood of 
elevated CRP, an analysis comparing controls to cases would 
have been biased by underestimating specificity for bacte-
rial pneumonia. Even with the targeted sampling of controls 
for CRP testing, 88% of tested HIV-negative controls had 
CRP levels <10 mg/L. Nevertheless, the 3% found with CRP 
≥40 mg/L demonstrates the lack of perfect specificity of this 
marker for identifying bacterial pneumonia. Of the 168 tested 
HIV-negative controls who did not have an RTI nor high-den-
sity Spn in NP/OP nor Spn detected in whole blood by PCR, 
1 (0.6%) still had CRP ≥40 mg/L. This child, who had a CRP 
level of 81.3 mg/L, was 5 months of age from the Mali site with 
no signs of illness or malnutrition and no apparent factors for 
elevated CRP.
Combining CRP with pathogen-specific measurements 
increased their specificity for distinguishing bacterial from RSV 
etiology as we demonstrated for Spn without substantial loss to 
sensitivity. But CRP does not distinguish between bacterial eti-
ologies even though CRP was somewhat higher among cases 
confirmed for Spn or Hinf than among cases confirmed for 
other bacteria.
For pneumonia, identifying cases with a confirmed etiology 
is possible in only a small subset because lung aspirates and 
Table 2. C-Reactive Protein Combined With Pneumococcal Nasopharyngeal/Oropharyngeal and Whole-Blood Polymerase Chain Reaction Density 
Measures for Distinguishing Confirmed Pneumococcal Pneumonia From Respiratory Syncytial Virus–Positive Cases, Controls Targeted for CRP Testing, 
and Confirmed Other Bacterial Cases
Density Measure
Confirmed Spn 
Casesa
RSV+ 
Casesb
Controls 
Targeted for 
CRP Testingc
Confirmed Non- 
Spn Bacterial 
Casesd
NP/OP PCR Spn density (n = 36) (n = 858) (n = 597) (n = 79)
 NP/OP PCR density > 106.9 copies/mLe alone 21 (58.3) 109 (12.7) 73 (12.2) 20 (25.3)
 + CRP ≥40 mg/L 17 (47.2) 33 (3.9) 3 (0.5) 17 (21.5)
 + CRP ≥100 mg/L 15 (41.7) 8 (0.9) 0 (0.0) 14 (17.7)
Whole-blood PCR Spn density (n = 35) (n = 847) (n = 597) (n = 78)
 Density >102.2 copies/mLe alone 18 (51.4) 19 (2.2) 119 (19.9) 4 (5.1)
 + CRP ≥40 mg/L 17 (48.6) 3 (0.4) 5 (0.8) 3 (3.9)
 + CRP ≥100 mg/L 16 (45.7) 1 (0.1) 1 (0.2) 1 (1.3)
NP/OP PCR Spn density or whole-blood PCR Spn density (n = 34) (n = 835) (n = 593) (n = 77)
 (NP/OP density >106.9 copies/mL or whole-blood density >102.2 copies/mL)e alone 27 (79.4) 126 (15.1) 179 (30.2) 23 (29.9)
 + CRP ≥40 mg/L 23 (67.7) 35 (4.2) 8 (1.4) 19 (24.7)
 + CRP ≥100 mg/L 21 (61.8) 9 (1.1) 1 (0.2) 15 (19.5)
NP/OP PCR Spn density and whole-blood PCR Spn density (n = 37) (n = 870) (n = 601) (n = 80)
 (NP/OP density >106.9 copies/mL and whole-blood density >102.2 copies/mL)e alone 12 (32.4) 2 (0.2) 13 (2.2) 1 (1.3)
 + CRP ≥40 mg/L 11 (29.7) 1 (0.1) 0 (0.0) 1 (1.3)
 + CRP ≥100 mg/L 10 (27.0) 0 (0.0) 0 (0.0) 0 (0.0)
Data are presented as No. (%) positive unless otherwise indicated.
Abbreviations: CRP, C-reactive protein; NP/OP, nasopharyngeal/oropharyngeal; PCR, polymerase chain reaction; RSV, respiratory syncytial virus; Spn, Streptococcus pneumoniae.
aSpn detected by blood culture, by lung aspirate culture or PCR, or by pleural fluid culture or PCR or BinaxNOW assay.
bRSV detected by NP/OP PCR or induced sputum PCR, excluding confirmed Spn cases and confirmed other bacterial cases.
cControls selected for CRP testing were children more likely to have elevated CRP levels (a higher proportion had respiratory symptoms, were whole-blood Spn PCR positive, and/or had 
high total NP/OP pathogen load compared to controls not tested).
dAny non-Spn bacterial pathogen detected by blood culture, by lung aspirate culture or PCR, or by pleural fluid culture or PCR.
eCut-points obtained from receiver operating characteristic analyses that maximized Youden index in distinguishing confirmed Spn cases from community controls.
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pleural fluid specimens are obtained from very few cases and 
blood culture has low sensitivity, especially when blood culture 
volume is low or antibiotics are administered prior to specimen 
collection. Therefore, because few bacterial pneumonia cases 
have a confirmed etiology, the RSV pneumonia cases in our 
analysis could have included children with undetected bacte-
rial coinfection. Misclassifications of this type would result in 
overestimating the proportion of RSV pneumonia cases with 
elevated CRP, and thus the specificity of CRP for detecting bac-
terial compared to viral pneumonia may be higher.
Our analyses showed that elevated CRP was positively asso-
ciated with confirmed bacterial pneumonia, especially Spn and 
Hinf, and negatively associated with RSV pneumonia. However, 
the variation in the distribution of CRP among study sites for 
both cases and controls and by clinical factors such as HIV sug-
gests that optimal cut-points for diagnostic utility may vary by 
setting or geographic location. While CRP had imperfect spec-
ificity for distinguishing bacterial from RSV pneumonia and 
therefore limited use as a diagnostic tool, the clear association 
of elevated CRP with bacterial pneumonia makes it potentially 
useful in epidemiologic studies on bacterial pneumonia, as 
cases with low CRP could be assumed to have lower probability 
of bacterial etiology than cases with high CRP. The role of CRP 
in discriminating between bacterial pneumonia and viral pneu-
monias other than RSV warrants further study.
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